Age-Related Muscle Loss: No Approved Drug Yet, Many Candidates
Graded Preliminary — a review that describes drug approaches without analysing new data; it does not show whether any of these drugs help older people.
Cell, tissue or computational study. Not evidence about people yet, which is why the grade is capped at Preliminary.
- Design
- Narrative review
- Participants
- N/A
- Duration
- —
- Funding
- One author cofounded Epirium Bio and holds equity; two hold patents on…
There is still no approved drug for age-related muscle loss, but candidates are aimed at several different causes.
As people age, they lose muscle mass and strength. Doctors call this sarcopenia. It makes people less mobile, leads to falls and broken bones, and raises the risk of death. Yet there is no approved drug for it. One reason is that many different causes work together.
A review in the journal Nature Reviews Drug Discovery describes drug candidates that target these causes. Some aim to strengthen mitochondria, the power plants of cells, for example molecules related to NAD+ or urolithin A. Others aim to restart the cell's cleanup system. Further candidates are meant to boost growth signals in muscle, support blood supply or calm the low-level inflammation of old age. One approach blocks an enzyme called 15-PGDH. This is meant to restore nerve supply, muscle building and repair.
The authors also note a trend: more and more trials combine GLP-1 weight-loss drugs with drugs meant to preserve muscle. The article describes approaches and does not analyse new data. It does not show that any of these drugs actually helps older people.
Conflict of Interest Disclosure: One author cofounded Epirium Bio and holds equity; two hold patents on blocking 15-PGDH, and two now work for Nestlé and Regeneron.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.